Log in to your Inderes Free account to see all free content on this page.
Sprint Bioscience
1.53 SEK
-4.09 %
Less than 1K followers
SPRINT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-4.09 %
+116.62 %
+150.00 %
+264.83 %
-1.98 %
-7.59 %
+143.06 %
-75.85 %
-87.01 %
Sprint Bioscience is a research company. The company develops drug candidates that can fight cancer individually or in combination with other drugs. The company has a portfolio of projects that are focused on attacking parts of the processes of cancer cells. The business model is based on a project portfolio and developing projects in parallel in the preclinical phase and then entering into licensing agreements with the global pharmaceutical industry. The company is headquartered in Huddinge.
Read moreMarket cap
160.91M SEK
Turnover
1.23M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
11.2.
2026
Annual report '25
All
Press releases
ShowingAll content types
BioStock: Sprint Bioscience: ”We have shown it's possible to make early deals”
BioStock: Sprint Bioscience sells cancer program TREX1 to Gilead
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio